SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID -- Ignore unavailable to you. Want to Upgrade?


To: Maurice Winn who wrote (1561)5/20/1998 10:55:00 AM
From: Bob L  Read Replies (2) | Respond to of 1762
 
I absolutely agree people should be free to try experimental drugs after learning the risks. But I do wonder if most intermediate and high grade patients would opt for rituxan with chop the first time around. I can't lay my hands on data right now, but isn't the initial response rate for chop alone almost 90%? So 97% for chop and rituxan sounds great at first, but maybe not so impressive after reviewing all the odds.